(NASDAQ: SUPN) Supernus Pharmaceuticals's forecast annual revenue growth rate of 4.59% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Supernus Pharmaceuticals's revenue in 2025 is $661,817,000.On average, 3 Wall Street analysts forecast SUPN's revenue for 2025 to be $34,862,850,492, with the lowest SUPN revenue forecast at $34,510,102,877, and the highest SUPN revenue forecast at $35,121,829,753. On average, 3 Wall Street analysts forecast SUPN's revenue for 2026 to be $38,234,213,493, with the lowest SUPN revenue forecast at $36,954,777,802, and the highest SUPN revenue forecast at $39,243,172,138.
In 2027, SUPN is forecast to generate $42,464,226,702 in revenue, with the lowest revenue forecast at $42,368,783,914 and the highest revenue forecast at $42,559,669,490.